Zhenzhen Li1, Xianghua Liu2, Baoying Wang3, Yali Nie4, Jianguo Wen5, Qingwei Wang5, Chaohui Gu5. 1. The Institute of Clinical Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 2. Pathological Experiment Center, Henan University of Traditional Chinese Medicine, Zhengzhou, China. 3. Pharmacology and Toxicology Experiment Center, Pharmacology Department, Henan University of Traditional Chinese Medicine, Zhengzhou, China. 4. Pharmacology Department, School of Medicine, Zhengzhou University, Zhengzhou, China. 5. Urology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Abstract
AIM: Recent studies indicate that pirfenidone (PFD) may have anti-fibrotic effects in many tissues, but the potential molecular mechanism remains unknown. The purpose of this study is to investigate the potential effects of PFD on epithelial-to-mesenchymal transition (EMT) and renal fibrosis in a unilateral ureteral obstruction (UUO) rat model and the involved molecular mechanism related to cultured human renal proximal tubular epithelial cells (HK-2). METHODS: Sixty rats were randomly divided into three groups: sham-operated, vehicle-treated UUO, and PFD-treated UUO. Kidney specimens were collected at day 7 or 14 after UUO. PFD treatment was also performed for human HK-2. The tubulointerstitial injury, interstitial collagen deposition, and expression of type I and III collagen, α-SMA, S100A4, fibronection and E-cadherin were assessed. In addition, extracellular signal regulated kinase (ERK1/2), p38 MAPK (p38), and c-Jun N-terminal kinase/stress-activated protein kinase (JNK) were also detected. RESULTS: In vitro, PFD significantly attenuated TGF-β1-induced EMT and extracellular matrix (ECM) synthesis, as determined by reducing expression of α-SMA, type I and III collagen, S100A4, fibronection, and increased expression of E-cadherin. PFD treatment attenuated TGF-β1-induced up-regulation of phosphorylation of ERK1/2, p38 and JNK. In vivo, PFD reduced the degree of tubulointerstitial injury and renal fibrosis, which was associated with reduced expression of TGF-β1, type III collagen, α-SMA, S100A4, fibronection, and increased expression of E-cadherin. CONCLUSION: These results suggest that pirfenidone is able to attenuate EMT and fibrosis in vivo and in vitro through antagonizing the MAPK pathway, providing a potential treatment to alleviate renal tubulointerstitial fibrosis.
AIM: Recent studies indicate that pirfenidone (PFD) may have anti-fibrotic effects in many tissues, but the potential molecular mechanism remains unknown. The purpose of this study is to investigate the potential effects of PFD on epithelial-to-mesenchymal transition (EMT) and renal fibrosis in a unilateral ureteral obstruction (UUO) rat model and the involved molecular mechanism related to cultured human renal proximal tubular epithelial cells (HK-2). METHODS: Sixty rats were randomly divided into three groups: sham-operated, vehicle-treated UUO, and PFD-treated UUO. Kidney specimens were collected at day 7 or 14 after UUO. PFD treatment was also performed for humanHK-2. The tubulointerstitial injury, interstitial collagen deposition, and expression of type I and III collagen, α-SMA, S100A4, fibronection and E-cadherin were assessed. In addition, extracellular signal regulated kinase (ERK1/2), p38MAPK (p38), and c-Jun N-terminal kinase/stress-activated protein kinase (JNK) were also detected. RESULTS: In vitro, PFD significantly attenuated TGF-β1-induced EMT and extracellular matrix (ECM) synthesis, as determined by reducing expression of α-SMA, type I and III collagen, S100A4, fibronection, and increased expression of E-cadherin. PFD treatment attenuated TGF-β1-induced up-regulation of phosphorylation of ERK1/2, p38 and JNK. In vivo, PFD reduced the degree of tubulointerstitial injury and renal fibrosis, which was associated with reduced expression of TGF-β1, type III collagen, α-SMA, S100A4, fibronection, and increased expression of E-cadherin. CONCLUSION: These results suggest that pirfenidone is able to attenuate EMT and fibrosis in vivo and in vitro through antagonizing the MAPK pathway, providing a potential treatment to alleviate renal tubulointerstitial fibrosis.
Authors: Andrew J Haak; Megan A Girtman; Mohamed F Ali; Eva M Carmona; Andrew H Limper; Daniel J Tschumperlin Journal: Eur J Pharmacol Date: 2017-05-30 Impact factor: 4.432
Authors: Sin Young Choi; Zhe Hao Piao; Li Jin; Jung Ha Kim; Gwi Ran Kim; Yuhee Ryu; Ming Quan Lin; Hyung-Seok Kim; Hae Jin Kee; Myung Ho Jeong Journal: PLoS One Date: 2016-11-30 Impact factor: 3.240
Authors: Gwenda F Vasse; Mehmet Nizamoglu; Irene H Heijink; Marco Schlepütz; Patrick van Rijn; Matthew J Thomas; Janette K Burgess; Barbro N Melgert Journal: J Pathol Date: 2021-03-03 Impact factor: 7.996
Authors: Christopher Lambers; Michael Roth; Peter Jaksch; Gabriella Muraközy; Michael Tamm; Walter Klepetko; Bahil Ghanim; Feng Zhao Journal: Sci Rep Date: 2018-01-18 Impact factor: 4.379